Grant Mitchell — The Potential of AI Drug Rep...

Cliff Asness — co-founder, managing principal, and chief investment officer at AQR Capital Management — is one of the most influential quantitative investors of the last 30 years. He's also one of the most candid. In this conversation, Cliff joins Infinite Loops to talk about why ...  Show more

Tomás Pueyo, the French-Spanish engineer and writer behind the successful "Uncharted Territories" Substack, joins us to dismantle the invisible forces that shape our history and future. We cover why humans are horrible at understanding exponential change, the geographical advanta ...  Show more

When Ziad Obermeyer was a resident in an emergency medicine program, he found himself lying awake at night worrying about the complex elements of patient diagnoses that physicians could miss. He subsequently found his way to data science and research and has since coauthored nume ...  Show more

Vaccine-maker Moderna is also a data company, and that’s enabling it to use AI to drastically reduce drug-development times, Chief Information Officer Brad Miller tells Bloomberg Intelligence’s Sam Fazeli and Mandeep Singh. This episode of the Tech Disruptors podcast looks at a w ...  Show more

In this fascinating episode of Brainfluence, pioneering neuromarketer Dr. Carl Marci discusses how modern technology is impacting our brains. He shares insights from his new book Rewired, explaining how excessive smartphone use and constant multitasking are reducing productivi ...

It may seem intuitive that AI and deep learning can speed up workflows — including novel drug discovery, a typically years-long and several-billion-dollar endeavor. But professors Artem Cherkasov and Olexandr Isayev were surprised to find that no recent academic papers provided a ...  Show more